28 May 2021 | 09:46am
StockMarketWire.com - Cancer therapies and diagnostics Avacta said it had yet to receive any update from the UK Medicines and Healthcare products Regulatory Agency on the CE mark submission for its SARS-CoV-2 antigen lateral flow test.
Its partner, Mologic Limited had filed the CE application. To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so, the company said.
At 9:46am: [LON:AVCT] Avacta Group PLC share price was 0p at 111.5p
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
26 May 2021 | 07:21am
StockMarketWire.com - IT group Softcat upgraded its annual earnings guidance after it achieved double-digit revenue growth in the third quarter, though it also warned of a flat performance in the following financial year.
Softcat said it now expected results for the year through July to be ahead of expectations .
The company delivered further double-digit year-on-year growth in revenue, gross profit and operating profit in the three months through April.
The improvements reflected performance that was generally more broad-based than that seen in the first half, it added.
Looking further ahead, however, Softcat said cost savings related to Covid were expected to reverse as it entered the next financial year.